Latest

2 stories

Hide weekly roundups

Wednesday, September 2

Quarterly updateScribe Therapeutics, Inc.

Scribe Therapeutics starts Phase 1 trial of PCSK9 silencer STX-1150, completes upsized IPO

Cardiovascular gene-editing company reports first clinical data expected in H1 2027 and cash runway into H1 2029 after $155.5 million IPO and Sanofi private placement.

SEC filing

Friday, July 24

FinancingScribe Therapeutics, Inc.

Scribe Therapeutics prices $128.7 million IPO at $15 per share

The clinical-stage CRISPR company will sell 8,580,000 shares on Nasdaq under "SCTX," with a Sanofi affiliate committing to a concurrent private placement.

SEC filing